Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.
Day BW, Stringer BW, Spanevello MD, Charmsaz S, Jamieson PR, Ensbey KS, Carter JC, Cox JM, Ellis VJ, Brown CL, Walker DG, Inglis PL, Allan S, Reynolds BA, Lickliter JD, Boyd AW. Day BW, et al. Among authors: charmsaz s. Neuro Oncol. 2011 Nov;13(11):1202-12. doi: 10.1093/neuonc/nor119. Epub 2011 Aug 16. Neuro Oncol. 2011. PMID: 21846680 Free PMC article.
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.
Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW. Day BW, et al. Among authors: charmsaz s. Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007. Cancer Cell. 2013. PMID: 23410976 Free article.
Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma.
Stringer BW, Bunt J, Day BW, Barry G, Jamieson PR, Ensbey KS, Bruce ZC, Goasdoué K, Vidal H, Charmsaz S, Smith FM, Cooper LT, Piper M, Boyd AW, Richards LJ. Stringer BW, et al. Among authors: charmsaz s. Oncotarget. 2016 May 17;7(20):29306-20. doi: 10.18632/oncotarget.8720. Oncotarget. 2016. PMID: 27083054 Free PMC article.
Eph receptors as oncotargets.
Charmsaz S, Boyd AW. Charmsaz S, et al. Oncotarget. 2017 Sep 19;8(47):81727-81728. doi: 10.18632/oncotarget.21045. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137214 Free PMC article. No abstract available.
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
Charmsaz S, Al-Ejeh F, Yeadon TM, Miller KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou C, Yarranton GT, Woronicz J, Scott AM, Lackmann M, Boyd AW. Charmsaz S, et al. Leukemia. 2017 Aug;31(8):1779-1787. doi: 10.1038/leu.2016.371. Epub 2016 Dec 6. Leukemia. 2017. PMID: 27922598
S100β as a serum marker in endocrine resistant breast cancer.
Charmsaz S, Hughes É, Bane FT, Tibbitts P, McIlroy M, Byrne C, Cocchiglia S, McBryan J, Hennessy BT, Dwyer RM, Kerin MJ, Hill AD, Young LS. Charmsaz S, et al. BMC Med. 2017 Apr 12;15(1):79. doi: 10.1186/s12916-017-0836-2. BMC Med. 2017. PMID: 28399921 Free PMC article. Clinical Trial.
30 results